Shanghai Fosun Pharma executes share buyback on HKEX

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX: 2196) announced a repurchase of 606,100 ordinary shares on the Hong Kong Stock Exchange on June 27, 2025. The shares were bought back at prices ranging from RMB 24.7 to RMB 24.76 per share, with the total cost of the repurchase amounting to RMB 14,997,260. Following the buyback, the company's number of issued shares (excluding treasury shares) decreased to 2,099,115,373 and number of treasury shares rose to 19,373,452, while the total number of issued shares stands at 2,118,488,825. The repurchase was conducted on the Shanghai Stock Exchange and is within a repurchase mandate approved by shareholders. The company is adhering to a moratorium on new share issuance or treasury share sales after the repurchase.